ENGLEWOOD, Colo., June 11, 2021 /PRNewswire/ -- Ampio
Pharmaceuticals (NYSE American: AMPE), a clinical stage
biopharmaceutical company focused on the advancement of
immunology-based therapies for prevalent inflammatory conditions,
today announced that management will participate in a series of
one-on-one meetings with institutional investors throughout the day
at the Alliance Global Partners' Virtual Summer Healthcare
Symposium on June 17, 2021.
Due to the invitation-only format of the event, no webcast will
be available.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company
primarily focused on the advancement of immunology-based therapies
to treat prevalent inflammatory conditions for which there are
limited treatment options. Ampio's lead drug, Ampion™, is backed by
an extensive patent portfolio with intellectual property protection
extending through 2035 and will be eligible for 12-year FDA market
exclusivity upon approval as a novel biologic under the biologics
price competition and innovation act (BPCIA).
Forward Looking Statements
Ampio's statements in this press release that are not historical
fact, and that relate to future plans or events, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of words such as "believe,"
"expect," "plan," "anticipate," and similar expressions. These
forward-looking statements include statements regarding Ampio's
expectations with respect to Ampion and its classification, as well
as those associated with regulatory approvals and other FDA
decisions, the Biological License Application ("BLA"), the ability
of Ampio to enter into partnering arrangements,
clinical trials and decisions and changes in business conditions
and similar events, the ability to receive regulatory approval to
conduct clinical trials, that Ampion may be used to treat ARDS
induced by COVID-19, all of which are inherently subject to various
risks and uncertainties. The risks and uncertainties involved
include those detailed from time to time in Ampio's filings with
the Securities and Exchange Commission, including without
limitation, under Ampio's Annual Report on Form 10-K and other
documents filed with the Securities and Exchange Commission. Ampio
undertakes no obligation to revise or update these forward-looking
statements, whether as a result of new information, future events
or otherwise.
Media Contact
Katie
Kennedy
katie@gregoryfca.com
610-731-1045
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ampio-pharmaceuticals-to-participate-in-the-alliance-global-partners-virtual-summer-healthcare-symposium-301310483.html
SOURCE Ampio Pharmaceuticals, Inc.